{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:16:40Z","timestamp":1783523800653,"version":"3.55.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:p>Introduction: Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) is a preferred antiretroviral regimen in international guidelines, but long-term real-world data in Latin American people living with HIV (PLWH) are scarce. This study describes 48-month persistence, virological effectiveness, safety and metabolic changes in the Argentine BICTARG cohort.\n\nMaterial and methods: We conducted an observational, retrospective, open cohort study including treatment-na\u00efve (TN) and treatment-experienced (TE) adults with HIV who initiated B\/F\/TAF between October 2019 and December 2022 at a large HIV centre. Persistence on B\/F\/TAF, virological suppression (VS, &lt;50 copies\/mL), B\/F\/TAF-related adverse events (AEs), and metabolic parameters (fasting glucose, cholesterol, and triglycerides) were assessed at 24, 36 and 48 months.\n\nResults: Overall, 3,057 PLWH were included: 425 TN (14%) and 2,632 TE (86%). In TN, persistence at 24, 36 and 48 months was 99%, 97% and 95%, and VS rates were 95%, 93% and 90%, respectively, with no AEs reported. In TE, persistence was 98%, 96%, and 88%, and VS rates were 96%, 98%, and 98%; AE rates were \u22640.4%, with no virological failure. Fasting glucose remained unchanged; TN participants showed increases in total, LDL, and HDL cholesterol, whereas in TE participants, lipid levels were stable and triglycerides decreased over time (p&lt;0.001).\n\nConclusions: In this large Argentine cohort, B\/F\/TAF demonstrated high persistence, sustained VS, low AE rates and an overall favourable metabolic profile over 48 months in both TN and TE PLWH, providing the first long-term real-world evidence from Latin America.<\/jats:p>","DOI":"10.37201\/req\/187.2026","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:56:48Z","timestamp":1781611008000},"page":"357","source":"Crossref","is-referenced-by-count":0,"title":["Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir\/emtricitabine\/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort"],"prefix":"10.37201","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-6132","authenticated-orcid":false,"given":"Diego","family":"Cecchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-449X","authenticated-orcid":false,"given":"Mart\u00edn","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1893-5444","authenticated-orcid":false,"given":"Gast\u00f3n","family":"Copertari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-2783","authenticated-orcid":false,"given":"Brenda","family":"Bacelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3512-4791","authenticated-orcid":false,"given":"Cinthia","family":"Lamaizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-1868","authenticated-orcid":false,"given":"Macarena","family":"Roel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0602-5175","authenticated-orcid":false,"given":"Edgardo","family":"Bottaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4399-2628","authenticated-orcid":false,"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"23328","published-online":{"date-parts":[[2026,6,16]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:37:28Z","timestamp":1783521448000},"score":1,"resource":{"primary":{"URL":"https:\/\/revespquimioterapia.com\/articulo\/long-term-persistence-effectiveness-safety-and-metabolic-impact-of-bictegravir-emtricitabine-tenofovir-alafenamide-fixed-dose-combination-in-people-living-with-hiv-in-the-bictarg-cohort-63955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,16]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/187.2026","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}